Castle Biosciences (CSTL) Stephens 26th Annual Investment Conference | NASH2024 summary

Business focus and product portfolio

• Focuses on high-value molecular diagnostic tests that impact clinical management decisions, especially in dermatology and gastroenterology.

• TissueCypher test addresses risk stratification in Barrett's esophagus, targeting about 415,000 patients annually.

• Main revenue drivers are dermatology tests for melanoma and squamous cell carcinoma, with additional products in gastroenterology and mental health.

• Plans to expand the GI product portfolio in the future, leveraging the existing sales force.

Financial performance and guidance

• Q3 revenue reached approximately $86 million, with full-year guidance raised to $320–$330 million.

• Adjusted EBITDA for the quarter was about $23 million.

Sales team expansion and market penetration

• TissueCypher sales team expanded from 16 to 40 representatives between early 2022 and Q2 2024.

• Market penetration for TissueCypher reached about 5.5% by the end of Q3, outpacing earlier melanoma test adoption.

• Target audience includes roughly 10,000 gastroenterologists, with optimal sales force size projected at 60–65.

• Sales team efficiency is higher in gastroenterology due to larger practice sizes compared to dermatology.